Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

rx pharma-pack, inc. - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride anhydrous 5 mg in 1 ml - marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of marcaine in these patients. marcaine is not recommended for intravenous regional anesthesia (bier block). see warnings . the routes of administration and indicated marcaine concentrations are: - local infiltration - peripheral nerve block - retrobulbar block - sympathetic block - lumbar epidural  0.25%, 0.5%, and 0.75% (0.75% not for obstetrical anesthesia) - caudal - epidural test dose - dental blocks (see dosage and administration for additional information). standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of mar

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

rx pharma-pack, inc. - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride anhydrous 5 mg in 1 ml - marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of marcaine in these patients. marcaine is not recommended for intravenous regional anesthesia (bier block). see warnings . the routes of administration and indicated marcaine concentrations are: - local infiltration - peripheral nerve block - retobulbar block - sympathetic block - lumbar epidural  0.25%, 0.5%, and 0.75%  (0.75% not for obstetrical anesthesia) - caudal - epidural test dose - dental blocks (see dosage and administration for additional information). standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of ma

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

dr.reddy's laboratories limited - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - fexofenadine hcl 180 mg and pseudoephedrine hcl 240 mg extended-release tablets (24 hour formulation) are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion.  fexofenadine hcl 180 mg and pseudoephedrine hcl 240 mg extended-release tablets (24 hour formulation) should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology ). fexofenadine hcl 180 mg and pseudoephedrine hcl 240 mg extended-release tablets (24 hour formulation) are contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, fexofenadine hcl 180 mg and pseudoephedrine hcl  240 mg extended-release tablets (24 hour formulation) are contrai

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

general injectables & vaccines, inc - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - lidocaine hydrochloride and epinephrine injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection, by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

cantrell drug company - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 10 mg in 1 ml

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

andersen pharma llc - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aurohealth llc - pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - pseudoephedrine hydrochloride 120 mg - nasal decongestant - temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies - temporarily relieves sinus congestion and pressure if you are now taking a prescription monoamine oxidase inhibitor (maoi) (certain drugs for depression, psychiatric or emotional conditions, or parkinson’s disease), or for 2 weeks after stopping the maoi drug. if you do not know if your prescription drug contains an maoi, ask a doctor or pharmacist before taking this product. - heart disease - high blood pressure - thyroid disease - diabetes - trouble urinating due to an enlarged prostate gland -  nervousness, dizziness, or sleeplessness occur - symptoms do not improve within 7 days or occur with a fever

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

chain drug consortium, llc - pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - pseudoephedrine hydrochloride 120 mg - nasal decongestant - temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies - temporarily relieves sinus congestion and pressure

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

wockhardt usa, inc. - triprolidine hydrochloride (unii: yan7r5l890) (triprolidine - unii:2l8t9s52qm), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f), codeine phosphate (unii: gsl05y1mn6) (codeine - unii:q830pw7520) - syrup - 1.25 mg in 5 ml - pseudodine™ c cough syrup is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. pseudodine™ c cough syrup is contraindicated under the following conditions: this drug should not be used in newborn or premature infants. antihistamines should not be used to treat lower respiratory tract symptoms, including asthma. (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine. sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (mao) inhibitor therapy (see precautions, drug interactions ). like other medications containing a narcotic, pseudodine™ c cough syrup is controlled by the drug enforcement administration. it is classified under schedule v. codeine can produce drug dependence of the morphine typ

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

akorn - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations ]. animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. these